NCT02251938View on ClinicalTrials.gov

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 29, 2014

Primary Completion Date

November 1, 2017

Study Completion Date

November 27, 2017

Conditions
Non-Infectious Uveitis of the Posterior Segment of the Eye
Interventions
DRUG

DE-109 440 μg

Medium Dose

Trial Locations (25)

60304

Oak Park

Unknown

Phoenix

Sacramento

Golden

Tampa

Jackson

St Louis

New Brunswick

Palisades Park

New York

Orchard Park

Austin

Salt Lake City

Graz

Paris

Hyderabad

Aurobindo Marg

Daryāganj

Bhubaneswar

Chennai

Madurai

Noida

Milan

Ankara

Izmir

All Listed Sponsors
lead

Santen Inc.

INDUSTRY

NCT02251938 - A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program | Biotech Hunter | Biotech Hunter